Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40265-021-01488-z http://scihub22266oqcxt.onion/10.1007/s40265-021-01488-z 33788181!8010786!33788181     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33788181&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Drugs 2021 ; 81 (5): 605-610 Nephropedia Template TP {{tp|p=33788181|t=2021. Voclosporin: First Approval |pdf=|usr=}}{{33788181}} gab.com Text Voclosporin: First Approval JO: Drugs http://www.kidney.de/pget.php?&tw=1&pmid=33788181 #FOAvip Voclosporin (Lupkynis()) is an oral calcineurin inhibitor immunosuppressant that is being developed by Aurinia Pharmaceuticals. In January 2021, based on positive results from the pivotal phases II and III trials, oral voclosporin received its first approval in the USA for use in combination with a background immunosuppressive therapy regimen for adults with active lupus nephritis. Voclosporin is also being explored for the novel coronavirus disease 2019 (COVID-19) in kidney transplant recipients. This article summarizes the milestones in the development of voclosporin leading to this first approval for lupus nephritis. Twit Text FOAVip Voclosporin: First Approval ????Drugs http://www.kidney.de/pget.php?&tw=1&pmid=33788181 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33788181 #FOAvip English Wikipedia <ref>{{Cite pmid|33788181}}</ref> Voclosporin: First Approval #MMPMID33788181 Heo YA Drugs 2021[Apr]; 81 (5): 605-610 PMID33788181show ga Voclosporin (Lupkynis()) is an oral calcineurin inhibitor immunosuppressant that is being developed by Aurinia Pharmaceuticals. In January 2021, based on positive results from the pivotal phases II and III trials, oral voclosporin received its first approval in the USA for use in combination with a background immunosuppressive therapy regimen for adults with active lupus nephritis. Voclosporin is also being explored for the novel coronavirus disease 2019 (COVID-19) in kidney transplant recipients. This article summarizes the milestones in the development of voclosporin leading to this first approval for lupus nephritis. |*COVID-19 Drug Treatment[MESH] |*Kidney Transplantation[MESH] |Animals[MESH] |COVID-19/complications[MESH] |Calcineurin Inhibitors/pharmacokinetics/pharmacology/*therapeutic use[MESH] |Cyclosporine/pharmacokinetics/pharmacology/*therapeutic use[MESH] |Drug Approval[MESH] |Humans[MESH] |Immunosuppressive Agents/pharmacokinetics/pharmacology/*therapeutic use[MESH]Voclosporin: First Approval (epmc).pdf DeepDyve Pubget Overpricing